Skip to main content

Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO), CF

R&D Systems, part of Bio-Techne | Catalog # AVI10579

Biotinylated
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AVI10579-020

Key Product Details

Learn more about Avi-tag Biotinylated Proteins

Source

CHO

Accession #

Structure / Form

Biotinylated via Avi-tag

Conjugate

Biotin

Applications

Bioactivity, Enzyme Activity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human ACE-2 protein
          
Human ACE-2
(Gln18 - Ser740)
Accession # Q9BYF1.2
10-His tag Avi-tag
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Protein identity confirmed by mass spectrometry.

Predicted Molecular Mass

87 kDa

SDS-PAGE

103-113 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant SARS-CoV-2 Spike RBD Fc Chimera  (Catalog # 10499-CV) is immobilized at 0.2 µg/mL (100 µL/well), Biotinylated Recombinant Human ACE-2 His-tag Avi-tag (CHO Expressed) (Catalog # AVI10579) binds with an ED50 of 1.2-9.6 ng/mL.

Measured by its ability to cleave a fluorogenic peptide substrate, Mca-YVADAPK(Dnp)-OH (Catalog # ES007).
The specific activity is >700 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO), CF

Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO) Binding Activity

Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO) Binding Activity

When Recombinant SARS-CoV-2 Spike RBD Fc Chimera (10499-CV) is immobilized at 0.2 µg/mL (100 µL/well), Biotinylated Recombinant Human ACE-2 His-tag Avi-tag (CHO Expressed) (Catalog # AVI10579) binds with an ED50 of 1.2-9.6 ng/mL.
Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO) Enzyme Activity

Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO) Enzyme Activity

Biotinylated Recombinant Human ACE‑2 His-tag Avi-tag (CHO Expressed) (Catalog # AVI10579) is measured by its ability to cleave a fluorogenic peptide substrate, Mca-YVADAPK(Dnp)-OH (ES007).
Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO) SDS-PAGE

Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO) SDS-PAGE

2 μg/lane of Biotinylated Recombinant Human ACE-2 His-tag Avi-tag Protein (Catalog # AVI10579) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at ~109 kDa under reducing conditions.

Formulation, Preparation and Storage

AVI10579
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, ZnCl2 and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: ACE-2

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE (1, 2). ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues (1, 3). ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo (4-6), functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters (1, 2). Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury (4, 7), heart disease (8), liver and lung fibrosis (9), inflammatory lung disease (10), and cardiopulmonary disease (11). Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail (12). The N-terminal peptidase region is required for binding to SARS-CoV and SARSCoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters (2). The peptidase domain contains a long deep cleft that undergoes a large hinge-bending movement at substrate and inhibitor binding (12).  Classical ACE inhibitors such as captopril and lisinopril do not inhibit ACE-2 activity and inhibitors of ACE-2 do not inhibit ACE activity (13).

References

  1. Kuba, K. et al. (2010) Pharmacol. Ther. 128:119.
  2. Yan, R. et al. (2020) Science 367:1444.
  3. Tipnis, S.R. et al. (2000) J. Biol. Chem. 275:33238.
  4. Kuba, K. et al. (2005) Nature Med. 11:875.
  5. Hoffmann, M. et al. (2020) Cell.181:1.
  6. Wrapp, D. et al. (2020) Science 367:1260.
  7. Imai, Y. et al. (2005) Nature 436:112.
  8. Huang, L. et al. (2003) J. Biol. Chem. 278:15532.
  9. Schrom, E. et al. (2017) Mol. Therapy Nuc. Acid 7:350.
  10. Jia, H. et al. (2016) Shock. 46:239.
  11. Cole-Jeffrey, C.T. et al. (2015) J. Cardiovasc. Pharmacol. 66:540.
  12. Towler, P. et al. (2004) J. Biol. Chem. 279:17996.
  13. Crackower, M.A. et al. (2002) Nature 417:822.

Long Name

Angiotensin I Converting Enzyme 2

Alternate Names

ACE2, ACEH

Entrez Gene IDs

59272 (Human); 70008 (Mouse); 302668 (Rat); 100144303 (Porcine); 480847 (Canine); 418623 (Chicken); 102130864 (Cynomolgus Monkey); 554349 (Feline); 101673097 (Ferret); 101823817 (Hamster); 108390919 (Malayan Pangolin)

Gene Symbol

ACE2

UniProt

Additional ACE-2 Products

Product Documents for Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO), CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human ACE-2 His-tag Avi-tag Protein (CHO), CF

For research use only

Loading...
Loading...
Loading...